Skip to main content
Top
Gepubliceerd in: Tijdschrift voor Urologie 5/2016

25-05-2016 | Artikel

Klinische relevantie van incidentele prostaatlaesies op een FDG-PET/CT-scan

Dienen patiënten verder geëvalueerd te worden?

Auteurs: drs. Daan J. Reesink, drs. Elisabeth E. Fransen van de Putte, dr. Erik Vegt, dr. Jeroen de Jong, Erik van Werkhoven, dr. Laura S. Mertens, dr. Axel Bex, dr. Henk G. van der Poel, dr. Bas W. G. van Rhijn, prof. dr. Simon Horenblas, dr. Richard P. Meijer

Gepubliceerd in: Tijdschrift voor Urologie | Uitgave 5/2016

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Het doel van deze studie was het bepalen van de klinische relevantie van incidentele prostaatopname (IPO) op een FDG-PET/CT-scan. We analyseerden 108 mannelijke patiënten met blaascarcinoom (BCa) die een FDG-PET/CT-scan ondergingen en vervolgens een cystoprostatectomie, in de periode 2009–2014. IPO had een slechte voorspellende waarde voor de aanwezigheid van prostaatcarcinoom (PCa). Diagnostische nauwkeurigheid verbeterde niet wanneer een nucleair geneeskundige de laesies classificeerde op basis van de mate van verdenking op PCa. Gebaseerd op deze resultaten, zouden artsen bij IPO op een FDG-PET/CT-scan terughoudend moeten zijn met het toepassen van invasieve diagnostiek naar PCa.
Literatuur
1.
go back to reference Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–1403. doi:10.1016/j.ejca .2012.12.027.CrossRefPubMed Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–1403. doi:10.1016/j.ejca .2012.12.027.CrossRefPubMed
2.
go back to reference Von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology. 2006;238(2):405–422. doi:10.1148/radiol.2382041977.CrossRef Von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology. 2006;238(2):405–422. doi:10.1148/radiol.2382041977.CrossRef
3.
go back to reference Facey K, Bradbury I, Laking G, et al. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess (Rockv). 2007;11(44):iii–iv, xi–267 doi:10.3310/hta11440. Facey K, Bradbury I, Laking G, et al. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess (Rockv). 2007;11(44):iii–iv, xi–267 doi:10.3310/hta11440.
4.
go back to reference Effert PJ, Bares R, Handt S, et al. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol. 1996;155(3):994–998. doi:10.1016/S0022-5347(01)66366-3.CrossRefPubMed Effert PJ, Bares R, Handt S, et al. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol. 1996;155(3):994–998. doi:10.1016/S0022-5347(01)66366-3.CrossRefPubMed
5.
go back to reference Bouchelouche K, Oehr P. Positron emission Tomography and positron emission Tomography/computerized Tomography of urological malignancies: an update review. J Urol. 2008;179(1):34–45. doi:10.1016/j.juro.2007.08.176.CrossRefPubMed Bouchelouche K, Oehr P. Positron emission Tomography and positron emission Tomography/computerized Tomography of urological malignancies: an update review. J Urol. 2008;179(1):34–45. doi:10.1016/j.juro.2007.08.176.CrossRefPubMed
6.
go back to reference Kao P‑F, Chou Y‑H, Lai C‑W. Diffuse FDG uptake in acute prostatitis. Clin Nucl Med. 2008;33(4):308–310. doi:10.1097/RLU.0b013e3181662f8b.CrossRefPubMed Kao P‑F, Chou Y‑H, Lai C‑W. Diffuse FDG uptake in acute prostatitis. Clin Nucl Med. 2008;33(4):308–310. doi:10.1097/RLU.0b013e3181662f8b.CrossRefPubMed
7.
go back to reference Lawrentschuk N, Davis ID, Bolton DM, et al. Positron emission tomography and molecular imaging of the prostate: An update. BJU Int. 2006;97(5):923–931. doi:10.1111/j.1464-410X.2006.06040.x.CrossRefPubMed Lawrentschuk N, Davis ID, Bolton DM, et al. Positron emission tomography and molecular imaging of the prostate: An update. BJU Int. 2006;97(5):923–931. doi:10.1111/j.1464-410X.2006.06040.x.CrossRefPubMed
8.
go back to reference Takahashi N, Inoue T, Lee J, et al. The roles of PET and PET/CT in the diagnosis and management of prostate cancer. Oncology. 2008;72(3–4):226–233. doi:10.1159/000112946.CrossRef Takahashi N, Inoue T, Lee J, et al. The roles of PET and PET/CT in the diagnosis and management of prostate cancer. Oncology. 2008;72(3–4):226–233. doi:10.1159/000112946.CrossRef
9.
go back to reference Kinahan PE, Fletcher JW. Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR. 2010;31(6):496–505. doi:10.1053/j.sult.2010.10.001.CrossRefPubMedPubMedCentral Kinahan PE, Fletcher JW. Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR. 2010;31(6):496–505. doi:10.1053/j.sult.2010.10.001.CrossRefPubMedPubMedCentral
10.
go back to reference Han EJ, O JH, Choi WH, et al. Significance of incidental focal uptake in prostate on 18-fluoro-2-deoxyglucose positron emission tomography CT images. Br J Radiol. 2010;83(995):915–920. doi:10.1259/bjr/19887771.CrossRefPubMedPubMedCentral Han EJ, O JH, Choi WH, et al. Significance of incidental focal uptake in prostate on 18-fluoro-2-deoxyglucose positron emission tomography CT images. Br J Radiol. 2010;83(995):915–920. doi:10.1259/bjr/19887771.CrossRefPubMedPubMedCentral
11.
go back to reference Cho SK, Choi JY, Yoo J, et al. Incidental focal 18F-FDG uptake in the prostate: clinical significance and differential diagnostic criteria. Nucl Med Mol Imaging. 2010;45(3):192–196. doi:10.1007/s13139-011-0092-x.CrossRef Cho SK, Choi JY, Yoo J, et al. Incidental focal 18F-FDG uptake in the prostate: clinical significance and differential diagnostic criteria. Nucl Med Mol Imaging. 2010;45(3):192–196. doi:10.1007/s13139-011-0092-x.CrossRef
12.
go back to reference Hwang I, Chong A, Jung SI, et al. Is further evaluation needed for incidental focal uptake in the prostate in 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography images? Ann Nucl Med. 2013;27(2):140–145. doi:10.1007/s12149-012-0663-7.CrossRefPubMed Hwang I, Chong A, Jung SI, et al. Is further evaluation needed for incidental focal uptake in the prostate in 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography images? Ann Nucl Med. 2013;27(2):140–145. doi:10.1007/s12149-012-0663-7.CrossRefPubMed
13.
go back to reference Bhosale P, Balachandran A, Vikram R, et al. What is the clinical significance of FDG unexpected uptake in the prostate in patients undergoing PET/CT for other malignancies? Int J Mol Imaging. 2013;2013:1–6. doi:10.1155/2013/476786.CrossRef Bhosale P, Balachandran A, Vikram R, et al. What is the clinical significance of FDG unexpected uptake in the prostate in patients undergoing PET/CT for other malignancies? Int J Mol Imaging. 2013;2013:1–6. doi:10.1155/2013/476786.CrossRef
14.
go back to reference Seino H, Ono S, Miura H. Incidental prostate 18F-FDG uptake without calcification indicates the possibility of prostate cancer. Oncol Rep. 2014;31(4):1517–1522. doi:10.3892/or.2014.3011.PubMedPubMedCentral Seino H, Ono S, Miura H. Incidental prostate 18F-FDG uptake without calcification indicates the possibility of prostate cancer. Oncol Rep. 2014;31(4):1517–1522. doi:10.3892/or.2014.3011.PubMedPubMedCentral
15.
go back to reference Kang PM, Seo WI, Lee SS, et al. Incidental abnormal FDG uptake in the prostate on 18-fluoro-2-Deoxyglucose positron emission Tomography-computed Tomography scans. Asian Pac J Cancer Prev. 2014;15:8699–8703. doi:10.7314/APJCP.2014.15.20.8699.CrossRefPubMed Kang PM, Seo WI, Lee SS, et al. Incidental abnormal FDG uptake in the prostate on 18-fluoro-2-Deoxyglucose positron emission Tomography-computed Tomography scans. Asian Pac J Cancer Prev. 2014;15:8699–8703. doi:10.7314/APJCP.2014.15.20.8699.CrossRefPubMed
16.
go back to reference Yang Z, Hu S, Cheng J, et al. Prevalence and risk of cancer of incidental uptake in prostate identified by fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography. Clin Imaging. 2014;38(4):470–474. doi:10.1016/j.clinimag.2014.01.019.CrossRefPubMed Yang Z, Hu S, Cheng J, et al. Prevalence and risk of cancer of incidental uptake in prostate identified by fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography. Clin Imaging. 2014;38(4):470–474. doi:10.1016/j.clinimag.2014.01.019.CrossRefPubMed
17.
go back to reference Chun TY. Coincidence of bladder and prostate cancer. J Urol. 1997;157(1):65–67. doi:10.1016/S0022-5347(01)65281-9.CrossRefPubMed Chun TY. Coincidence of bladder and prostate cancer. J Urol. 1997;157(1):65–67. doi:10.1016/S0022-5347(01)65281-9.CrossRefPubMed
18.
go back to reference Kurokawa K, Ito K, Yamamoto T, et al. Comparative study on the prevalence of clinically detectable prostate cancer in patients with and without bladder cancer. Urology. 2004;63(2):268–272. doi:10.1016/j.urology.2003.09.027.CrossRefPubMed Kurokawa K, Ito K, Yamamoto T, et al. Comparative study on the prevalence of clinically detectable prostate cancer in patients with and without bladder cancer. Urology. 2004;63(2):268–272. doi:10.1016/j.urology.2003.09.027.CrossRefPubMed
19.
go back to reference Haas GP, Delongchamps N, Brawley OW, et al. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol. 2008;15(1):3866–3871.PubMedPubMedCentral Haas GP, Delongchamps N, Brawley OW, et al. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol. 2008;15(1):3866–3871.PubMedPubMedCentral
20.
go back to reference Damiano R, Di Lorenzo G, Cantiello F, et al. Clinicopathologic features of prostate Adenocarcinoma incidentally discovered at the time of radical Cystectomy: an evidence-based analysis. Eur Urol. 2007;52(3):648–657. doi:10.1016/j.eururo.2007.06.016.CrossRefPubMed Damiano R, Di Lorenzo G, Cantiello F, et al. Clinicopathologic features of prostate Adenocarcinoma incidentally discovered at the time of radical Cystectomy: an evidence-based analysis. Eur Urol. 2007;52(3):648–657. doi:10.1016/j.eururo.2007.06.016.CrossRefPubMed
21.
go back to reference Oyama N, Akino H, Suzuki Y, et al. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol. 1999;29(7):623–629. doi:10.1093/jjco/29.12.623.CrossRefPubMed Oyama N, Akino H, Suzuki Y, et al. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol. 1999;29(7):623–629. doi:10.1093/jjco/29.12.623.CrossRefPubMed
22.
go back to reference Shih WJ, Gross K, Mitchell B, et al. Prostate adenocarcinoma using Gleason scores correlates with prostate-specific antigen and prostate acid phosphatase measurements. J Natl Med Assoc. 1992;84(12):1049–1050.PubMedPubMedCentral Shih WJ, Gross K, Mitchell B, et al. Prostate adenocarcinoma using Gleason scores correlates with prostate-specific antigen and prostate acid phosphatase measurements. J Natl Med Assoc. 1992;84(12):1049–1050.PubMedPubMedCentral
23.
go back to reference Ross HM, Kryvenko ON, Cowan JE, et al. Do adenocarcinomas of the prostate with Gleason score (GS)≤6 have the potential to metastasize to lymph nodes? Am J Surg Pathol. 2012;36(9):1346–1352. doi:10.1097/PAS.0b013e3182556dcd.CrossRefPubMedPubMedCentral Ross HM, Kryvenko ON, Cowan JE, et al. Do adenocarcinomas of the prostate with Gleason score (GS)≤6 have the potential to metastasize to lymph nodes? Am J Surg Pathol. 2012;36(9):1346–1352. doi:10.1097/PAS.0b013e3182556dcd.CrossRefPubMedPubMedCentral
24.
go back to reference Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310–1319. doi:10.1056/NEJMoa0810696.CrossRefPubMedPubMedCentral Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310–1319. doi:10.1056/NEJMoa0810696.CrossRefPubMedPubMedCentral
25.
go back to reference Heijnsdijk EAM, Wever EM, Auvinen A, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med. 2012;367(7):595–605. doi:10.1056/NEJMoa1201637.CrossRefPubMed Heijnsdijk EAM, Wever EM, Auvinen A, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med. 2012;367(7):595–605. doi:10.1056/NEJMoa1201637.CrossRefPubMed
26.
go back to reference Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65(6):1046–1055. doi:10.1016/j.eururo.2013.12.062.CrossRefPubMedPubMedCentral Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65(6):1046–1055. doi:10.1016/j.eururo.2013.12.062.CrossRefPubMedPubMedCentral
27.
go back to reference Madalinska JB, Essink-Bot ML, De Koning HJ, et al. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol. 2001;19(6):1619–1628.PubMed Madalinska JB, Essink-Bot ML, De Koning HJ, et al. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol. 2001;19(6):1619–1628.PubMed
28.
go back to reference Mahal BA, Cooperberg MR, Aizer AA. Who bears the greatest burden of aggressive treatment of indolent prostate cancer? Am J Med. 2015; doi:10.1016/j.amjmed.2014.12.030.PubMed Mahal BA, Cooperberg MR, Aizer AA. Who bears the greatest burden of aggressive treatment of indolent prostate cancer? Am J Med. 2015; doi:10.1016/j.amjmed.2014.12.030.PubMed
30.
go back to reference Kim C, Lee S‑W, Yoon G, et al. Incidental detection of increased (18)F-FDG uptake and its follow-up in patients with granulomatous prostatitis after BCG treatment for urinary bladder cancer. Hell J Nucl Med. 2014;17(3):204–207. doi:10.1967/s002449910146.PubMed Kim C, Lee S‑W, Yoon G, et al. Incidental detection of increased (18)F-FDG uptake and its follow-up in patients with granulomatous prostatitis after BCG treatment for urinary bladder cancer. Hell J Nucl Med. 2014;17(3):204–207. doi:10.1967/s002449910146.PubMed
Metagegevens
Titel
Klinische relevantie van incidentele prostaatlaesies op een FDG-PET/CT-scan
Dienen patiënten verder geëvalueerd te worden?
Auteurs
drs. Daan J. Reesink
drs. Elisabeth E. Fransen van de Putte
dr. Erik Vegt
dr. Jeroen de Jong
Erik van Werkhoven
dr. Laura S. Mertens
dr. Axel Bex
dr. Henk G. van der Poel
dr. Bas W. G. van Rhijn
prof. dr. Simon Horenblas
dr. Richard P. Meijer
Publicatiedatum
25-05-2016
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Tijdschrift voor Urologie / Uitgave 5/2016
Print ISSN: 2211-3037
Elektronisch ISSN: 2211-4718
DOI
https://doi.org/10.1007/s13629-016-0124-5